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The discovery of animal cloning and subsequent development of cell reprogramming technology were quantum
leaps as they led to the achievement of rejuvenation by cell reprogramming and the emerging view that aging is a
reversible epigenetic process. Here, we will first summarize the experimental achievements over the last 7 years in
cell and animal rejuvenation. Then, a comparison will be made between the principles of the cumulative DNA
damage theory of aging and the basic facts underlying the epigenetic model of aging, including Horvath’s
epigenetic clock. The third part will apply both models to two natural processes, namely, the setting of the aging
clock in the mammalian zygote and the changes in the aging clock along successive generations in mammals. The
first study demonstrating that skin fibroblasts from healthy centenarians can be rejuvenated by cell reprogramming
was published in 2011 and will be discussed in some detail. Other cell rejuvenation studies in old humans and
rodents published afterwards will be very briefly mentioned. The only in vivo study reporting that a number of
organs of old progeric mice can be rejuvenated by cyclic partial reprogramming will also be described in some
detail. The cumulative DNA damage theory of aging postulates that as an animal ages, toxic reactive oxygen
species generated as byproducts of the mitochondria during respiration induce a random and progressive damage
in genes thus leading cells to a progressive functional decline. The epigenetic model of aging postulates that there
are epigenetic marks of aging that increase with age, leading to a progressive derepression of DNA which in turn
causes deregulated expression of genes that disrupt cell function. The cumulative DNA damage model of aging
fails to explain the resetting of the aging clock at the time of conception as well as the continued vitality of species
as millenia go by. In contrast, the epigenetic model of aging straightforwardly explains both biologic phenomena.
A plausible initial application of rejuvenation in vivo would be preventing adult individuals from aging thus
eliminating a major risk factor for end of life pathologies. Further, it may allow the gradual achievement of whole
body rejuvenation.
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The longing of man for eternal youth is universal and
time immemorial. Initially sought in religions, during
the Middle Ages, alchemists, a blend of mystics and
proto-chemists, tried to synthesize a mysterious potion,
the elixir of eternal youth, able to confer indefinite youth
to those that dare to drink it. Now, it seems that science* Correspondence: goya@isis.unlp.edu.ar
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cytoplasm of the oocyte.
The story of biological rejuvenation began in the early
1960s, with the discovery of animal cloning in frogs by
John Gurdon and collaborators [1]. Mammalian cloning
was achieved 30 years later, in 1996, with the birth of
Dolly, the sheep [2]. Cloning of other mammalian spe-
cies followed soon. It was clear that the cytoplasm of a
mature oocyte contained molecules able to turn a som-
atic nucleus into an embryonic one that could direct the
development of a new individual. At the time, it was
assumed that in the oocyte’s cytoplasm, there should be
a complex constellation of reprogramming factors,le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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years later, Takahashi and Yamanaka [3] demonstrated
that the transfer of only four master genes, namely oct4,
sox2, klf4, and c-myc (OSKM genes), to adult mouse fi-
broblasts was able to reprogram them, taking the cells to
a pluripotency stage in which they behave like embry-
onic stem cells. Cell reprogramming had been born, an
advance that paved the way for the subsequent imple-
mentation of cell rejuvenation. The studies on rejuven-
ation so far published are summarized below.
The achievement of cell and animal rejuvenation
To our knowledge, the first study reporting cell rejuven-
ation was published in 2011 [4]. It was a seminal piece
of work that merits to be described in some detail.
It was known that cells from old individuals display a
typical transcriptional signature, different from that of
young counterparts [5]. It was also known that fibro-
blasts from old donors have shortened telomeres [6] as
well as dysfunctional mitochondria and higher levels of
oxidative stress [7]. The French group first explored the
effect of cell reprogramming on the above features. InFig. 1 Rejuvenation by cell reprogramming of fibroblasts from healthy cen
typical transcriptional signature, different from that of young counterparts
potential, dysfunctional mitochondria, and higher levels of oxidative stress.
above alterations were reversed to embryonic levels. Then, iPSCs were diffe
appropriate set of differentiation factors. In the resulting cells, all of the abo
individuals, see [4] for further detailsorder to efficiently reprogram fibroblasts from healthy
centenarians and very old donors, the authors added the
pluripotency genes NANOG and LIN28 to the OSKM
reprogramming cocktail. This six-factor combination ef-
ficiently reprogrammed fibroblasts from very old donors
into typical induced pluripotent stem cells (iPSCs)
(Fig. 1). These blastocyst-like cells showed a higher
population-doubling (PD) potential than the cells of ori-
gin as well as elongated telomeres and a youthful
mitochondrial metabolism (estimated by measuring
mitochondrial transmembrane potential and clustering
transcriptome subsets involved in mitochondrial metab-
olism). Using an appropriate differentiation cocktail, the
iPSCs were differentiated back to fibroblasts, whose
transcriptional profile, mitochondrial metabolism, oxida-
tive stress levels, telomere length, and PD potential were
indistinguishable from those of fibroblasts from young
counterparts. Taken together, the data revealed that the
cells had been rejuvenated.
After Lapasset et al.’s paper, a core of independent stud-
ies followed which confirmed the initial findings. Thus, re-
programming of skin fibroblasts from aged humans totenarian individuals. In culture, fibroblasts from old individuals display a
as well as shortened telomeres, reduced population-doubling (PD)
When cells were reprogrammed to iPSC with a six-factor cocktail, the
rentiated back to fibroblasts by culture in the presence of an
ve variables had levels typical of fibroblasts taken from young
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(iNs), was shown to rejuvenate their transcriptome profile
and nucleocytoplasmic compartmentalization (NCC) to
that of wild-type fibroblasts from young donors [5]. When
iNs were generated by transdifferentiation, a procedure
that bypasses the pluripotency stage, the resulting neurons
retained the transcriptome signature of old fibroblasts and
showed a disrupted NCC as old fibroblasts do, which led
to the conclusion that transient dedifferentiation to the
iPSC stage is necessary to rejuvenate cells [5]. It is now
known that induced neurons generated by conventional
reprogramming and pluripotency factor-mediated direct
reprogramming (PDR) are rejuvenated whereas induced
neurons generated by transdifferentiation (also known as
lineage reprogramming (LR)) are not [8].
In an interesting study with skin fibroblasts from
healthy aged volunteers, it was observed that the lower
oxygen consumption typically observed in the mitochon-
dria of cells from old individuals was restored to youth-
ful levels after the old cells were dedifferentiated to
iPSCs and subsequently differentiated back to rejuve-
nated fibroblasts [9].
In 2013, Nishimura et al. [10] reprogrammed clonally
expanded antigen-specific CD8+ T cells from an
HIV-1-infected patient to pluripotency. The T
cell-derived iPSCs were then redifferentiated into CD8+
T cells that had a high proliferative capacity and elon-
gated telomeres.
Recently, rejuvenation of dysfunctional hematopoietic
stem cells (HSCs) from old mice was achieved by repro-
gramming them to the iPSC stage followed by differenti-
ating them back to HSCs. It was found that the
rejuvenated HSCs from old mice had the same func-
tional performance concerning the production of
different immune and erythroid cell lineages (peripheral
B-, T-, and granulocyte/myeloid cells, as well as bone
marrow erythroid progenitors) than HSCs from normal
young mice [11].
Another study reported that overexpression of the
pluripotency factor NANOG in progeroid or senescent
myogenic progenitors reversed cellular aging and fully
restored their ability to generate contractile force. The
effect was mediated by the reactivation of the ROCK
and TGF-β pathways [12]. For a more detailed descrip-
tion of references [5–11], see [13].
Until late 2016, it was believed that although cells
taken from old individuals could be fully rejuvenated, re-
juvenation in vivo was not possible as a continuous ex-
pression of the Yamanaka genes in animals had been
shown to cause multiple teratomas [14, 15]. However, in
December 2016, it was reported for the first time that
cells and organs can be rejuvenated in vivo [16]. Since it
was a quantum leap in rejuvenation technology, the
study will be described in some detail. The authors usedtransgenic progeric mice (LAKI mice) harboring a mu-
tated form of the human gene Lmna which causes the
accumulation of a truncated form of the nuclear mem-
brane protein Lamin A (progerin) present in progeric
patients. They also used transgenic wild-type mice (4F
mice) harboring two constructs. On chromosome 11,
there was a construct that expresses the OSKM genes
which are driven by a tetracycline-responsive (TRE) pro-
moter, and on chromosome 6, an expression cassette
was cloned which expresses the rtTA regulatory protein.
When the rtTA protein binds the antibiotic doxycycline
(DOX), a conformational allosteric change takes place so
that rtTA gains affinity for the TRE promoter turning on
the Yamanaka gene tandem [16]; (Fig. 2a–c). After re-
peated backcrossings, progeric transgenic mice express-
ing the 4F system (LAKI-4F mice) were generated [16].
Since the LAKI-4F mice age prematurely, by 2 months
of age, they are already senile. Thus, at age 2 months,
LAKI-4F mice began to be submitted to a rejuvenation
strategy based on the addition of DOX to the drinking
water of experimental mice in order to turn on the
Yamanaka genes; 2 days later, the antibiotic was removed
from the drinking water so that the transgenes were si-
lenced. Mice rested for 5 days after which DOX was
added again for 2 days then removed for 5 days and so
on, thus implementing a cyclic partial reprogramming
strategy (Fig. 2d–f ). After 6 weeks of partial reprogram-
ming cycles, the experimenters could observe some im-
provements in the external appearance of experimental
mice, including a reduction in spine curvature as com-
pared with untreated counterparts (controls). A sub-
group of the experimental and control mice was
sacrificed and some of their tissues and organs analyzed
(skin, kidneys, stomach, and spleen). Controls showed a
variety of alterations at an anatomical and histological
level in the above organs whereas some of these aging
signs disappeared or were attenuated in the experimental
mice. Some aging signs remained unchanged by the
treatment. Furthermore, although the experimental ani-
mals kept aging, they showed a 50% increase in mean
survival time as compared with wild-type progeric con-
trols. If the treatment was interrupted, the aging signs
came back.
An important implication of the study by Ocampo
et al. is that cyclic partial reprogramming causes some
epigenetic aging marks to be erased, but spares the dif-
ferentiation marks, which in turn suggest that both types
of epigenetic mark are not necessarily the same.
Theories of aging: cumulative DNA damage
versus epigenetic theories
Cumulative DNA damage
For several decades now, the theory of cumulative DNA
damage has remained widely accepted by mainstream
Fig. 2 Rejuvenation of transgenic progeric mice by cyclic partial cell reprogramming. A polycistronic cassette (4F system) harboring the four
Yamanaka genes under the control of a tetracycline-regulatable (Tet On) promoter (a) was transferred to one-cell embryos of C57bl/6 wild-type
mice in order to generate transgenic mice harboring the 4F system (4F mice) that were subsequently backcrossed with transgenic progeric mice
(LAKI mice). This way, progeric LAKI-4F mice were generated. The antibiotic doxycycline (DOX) binds to the regulatory rtTA protein which then
gains affinity for the Tet On promoter and binds to it turning on the Yamanaka genes (b). When DOX is removed from the medium, the rtTA
protein dissociates from the promoter and the transgenes become silent again (c). When DOX was added to the drinking water of 2-month-old
progeric mice, it turned on the Yamanaka genes and partial cell reprogramming began (d). Two days later, DOX was removed and the Yamanaka
genes silenced (e). After a 5-day resting period, DOX was added again for 2 days (f), then removed for 5 days and so on. This cyclic partial
reprogramming process rejuvenated some tissues and organs of the mice which survived 50% longer than the original progeric mice, see [16] for
further details
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consequence of the progressive accumulation of oxida-
tive damage to cell macromolecules, particularly DNA
[17, 18]. This phenomenon is thought to be especially
relevant in mitochondria where respiration is associated
with a continuous generation of reactive oxygen species
as byproducts of O2 reduction (Fig. 3a) [19, 20]. Accord-
ing to this model, the process is essentially irreversible
and can only be slowed down by appropriate interven-
tions like calorie restriction [21]. Indeed, the idea that a
progressive age-related deterioration of such an import-
ant molecule as DNA should play a central role in the
aging process sounds sensible. However, experimental
data from different sources do not support this model.
For instance, the naked mole rat, a small rodent whose
average lifespan (28.3 years) is nearly eight times longer
than it is in laboratory rodents, has been shown to pos-
sess high levels of oxidative damage in its cells even
when animals are young [22, 23]. It is likely that under
extreme environmental conditions such as a highly ion-
izing atmosphere, radioactive zones or high UV lightintensities, DNA damage may become a longevity-
determining factor. This will also be the case under nor-
mal environmental conditions in pathologies associated
with DNA repair defects, like Xeroderma pigmentosum.
However, wherever normal marine or terrestrial earth
conditions prevail, cumulative DNA damage does not
seem to play a relevant role in aging.
Epigenetic model
The growing evidence that reprogramming of somatic
cells from aged individuals rejuvenates them to their
embryonic stage is giving rise to the idea that the epige-
nome is the central driver of aging, at least in meta-
zoans, and that the process is reversible [24].
Studies in model organisms like yeasts, worms, and
flies have shown that aging is associated with progressive
changes in chromatin regulation. In young cells, the gen-
ome is in a relatively high level of repression which is in
part achieved by DNA methylation, and there are rela-
tively high levels of histone H3 trimethylated at lysine 9
(H3K9me3) and at lysine 27 (H3K27me3) and histone
Fig. 3 Diagrammatic representation of the cumulative DNA damage theory and the epigenetic model of aging. a Progressive age-related DNA
damage that takes place in the genome of cells with age due to environmental insults. ROS, reactive oxygen species. b The upper diagram
represents some of the progressive changes in histones H3 and H4 methylation and acetylation during normal aging. Changes in DNA
methylation are represented by stemmed asterisks on DNA. The lower diagram represents the chronologic changes that may occur on the same
epigenetic marks during OSKM gene-induced rejuvenation/dedifferentiation. Red symbols represent chromatin activating marks whereas black
symbols correspond to chromatin-repressor marks. Blue wavy lines represent the gene transcripts
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which are associated with transcriptionally repressed
chromatin, as well as relatively low levels of histone
H3 trimethylated at lysine 4 (H3K4me3) and histone
H4 acetylated at lysine 16 (H4K16ac), both of which
are associated with active chromatin [25]. Aging
seems to be associated with a progressive derepres-
sion of the transcriptional activity of chromatin,
which is effected in part by a reduction in DNA
methylation; a decrease of epigenetic repressor marks
like H3K9me3, H3K27me3, and H4K20me3 as well as
an increase in the levels of activation marks like
H3K4me3 and H4K16ac (Fig. 3b). Cell reprogram-
ming technology shows that this process is reversible
(Fig. 3b). The epigenetic model of aging provides an
elegant explanation for a number of age-relatedprocesses difficult to explain by conventional theories
of aging (see below).
The epigenetic clock theory
An important advance relevant to the epigenetic model
of aging is the relatively recent discovery that the level
of age-related methylation of a set of cytidine-guanosine
dinucleotides (CpG) located at precise positions
throughout the genome constitutes a highly reliable
biomarker of aging. A mathematical algorithm, the
multi-tissue age predictor also known as the epigenetic
clock, devised by Stephen Horvath [26], uses the
age-dependent methylation state (beta value) of 353
CpGs located at precise positions through the human
genome and generates a number, expressed in years, that
represents epigenetic age. In humans, the epigenetic age
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to chronological age and an error margin of 3.6 years
[27]. This is an unprecedented accuracy for a biomarker
of age, far superior to all biomarkers of age so far docu-
mented. Remarkably, the epigenetic clock predicts bio-
logical age with comparable high accuracy when applied
to DNA taken from the whole blood, peripheral blood
mononuclear cells, occipital cortex, buccal epithelium,
colon, adipose, liver, lung, saliva, and uterine cervix [27].
The rate of change in DNA methylation at age-
dependent CpGs represents the ticking rate of the epi-
genetic clock. The rate is very high in humans from
birth to 1 year of age; from 1 to 20 years of age, it pro-
gressively decelerates; and from age 20 onwards, it
changes to a much slower rate [27]. It can also be said
that the ticking rate of the epigenetic clock represents
the changing rate of DNA methylation heterogeneity
among cells in tissues. Now, it seems clear that lifespan
is associated not to the number of total tickings of the
epigenetic clock but to the rate of ticking after 20 years
of age when a human has achieved maturity. There is
compelling evidence that genetics is the primary control-
ler of the rate of epigenetic aging. For instance, it is
known that the rate of epigenetic aging is slower in
supercentenarians and their descendants [28]. It should
be pointed out that the epigenetic clock is an accurate
predictor of chronological age mainly in a context of
normal aging; under pathological circumstances, the epi-
genetic age displayed by the clock represents biological
rather than chronological age. For instance, pathologies
like Huntington’s and Parkinson’s diseases are associated
with accelerated epigenetic aging [29, 30]. Consistent
with the epigenetic model of aging, when 30-year-old
human [26] and 2-month-old mouse [31] somatic cells
are reprogrammed to iPSCs by the Yamanaka factors,
their epigenetic age reverts to zero years or months, re-
spectively. The epigenetic clock theory of aging hypothe-
sizes that biological aging is an unintended consequence
of both developmental and epigenetic maintenance pro-
grams for which the molecular footprints give rise to
DNA methylation (DNAm) age estimators [32]. Indeed,
the epigenetic clock theory and the epigenetic model of
aging go hand in hand and support each other.
The theories at work
The conception of a new individual involves the genesis
of a completely young organism which does not inherit
any aging trait from its parents, after conception life
starts anew. According to the cumulative DNA damage
theory, when a hypothetical human couple, 25 years of
age each member, conceive a new individual, the DNA
damage accumulated in the genome of their germ cells
during 25 years is probably minimal but higher than
zero. Therefore, the new zygote should inherit thatminimal damage (Fig. 4a, enlarged inset), and as a con-
sequence, it would not be fully young. In contrast, ac-
cording to the epigenetic model, the zygote conceived by
the same couple would have its epigenetic clock reset to
zero by the reprogramming factors present in the cyto-
plasm of that cell (Fig. 4b, enlarged inset). This hypoth-
esis is based on the fact that when human or mouse
adult somatic cells are reprogrammed to iPSCs, their
epigenetic age is reset virtually to zero [26, 31].
While every individual of a metazoan species ages,
complex animal life has remained viable over hundreds
of million years. According to the cumulative DNA dam-
age theory, germ cells are likely to sustain some accumu-
lation of DNA damage in spite of the fact that DNA is
highly protected in this type of cells. Since complex ani-
mal life emerged during the era of life evolution known
as the Cambrian explosion, some 550 million years ago
[33], the enormous number of generations of germ cells
that took place over the successive millennia during
which many complex animal species evolved should
have accumulated increasingly large amounts of DNA
damage that would be inherited by the zygotes they con-
ceive (Fig. 4a, main panel). Such accumulating DNA
damage should cause complex animal species to pro-
gressively weaken and eventually become extinct, which
obviously is not the case.
According to the epigenetic model, at the time of
fertilization, all the epigenetic marks of parental aging
are erased from the zygote’s genome, resetting its aging
clock back to zero. Therefore, in each generation, the
epigenetic clock of zygotes will restart from zero (Fig. 4b,
main panel), thus allowing that complex animal species
flourish and diversify over the millennia.
Therapeutic potential of cyclic partial
reprogramming
Besides showing that the OSKM genes are able to
partially rejuvenate cells and organs in mice, the same
study described above, Ocampo et al. [16], used
12-month-old, transgenic nonprogeroid mice. Cyclic
partial reprogramming enhanced the otherwise poor
regenerative capacity of their pancreas and skeletal
muscle and made these tissues more resilient to a subse-
quent insult.
Specifically, cyclic transient induction of OSKM trig-
gered proliferation of beta cells in the pancreas and sat-
ellite cells in the skeletal muscle, which are critical for
the maintenance of tissue homeostasis, but whose num-
bers typically decrease with age. Therefore, the benefits
of cyclic partial reprogramming may go beyond rejuven-
ation of old animals; it could also constitute an effective
regenerative treatment [34].
Concerning in vivo rejuvenation, the main challenges
that partial reprogramming in vivo presents are the need
Fig. 4 The two theories at work. a According to the cumulative DNA damage theory, when a hypothetical 25-year-old human couple conceives
a new individual, the zygote they conceived inherits the DNA damage of the parental germ cells. (Left enlarged panel) According to the theory,
after each generation, DNA damage in the successive zygotes would be accumulated through inherited damage, causing species viability to
decline progressively over the centuries, eventually driving them to extinction. (Main diagram) According to the epigenetic model, at the time of
fertilization, all the epigenetic marks of parental aging are erased from the zygote’s genome by the reprogramming factors present in the
cytoplasm, thus resetting its aging clock back to zero (b, left enlarged panel). Consequently, in each generation, the epigenetic clock of zygotes
will restart from zero, thus allowing that complex animal species flourish and diversify over time (b, main diagram)
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mals and that does not require indefinitely long applica-
tion of the method to prevent the rapid return of the
aging marks after termination of the treatment. Once such
hurdles are overcome, clinical treatment will become po-
tentially feasible. In such case, the first, more amenable,
clinical approach would be a preventive one in which
adult individuals carrying risk factors for late-life diseases
are submitted to a partial cell reprogramming approach
not necessarily to rejuvenate them but to stop or at least
significantly slow down their aging rate. In a more ad-
vanced stage of the partial reprogramming technology,
progressive rejuvenation of old individuals could be
attempted. At the increasing pace of technology advance-
ment, the above therapeutic aims may become available
routines in the not-too-distant future.
The possibility that human rejuvenation strategies may
become routine treatments raises some ethical issues, a
relevant one being a potential overpopulation of the
planet with the consequential impact on the availability
of food, energy, and other commodities. In any case,
these problems lie in the relatively distant future, and it
is to be hoped that more advanced societies willestablish regulatory legislation aimed at preventing a
demographic explosion.
Concluding remarks
The discovery of animal cloning and subsequent devel-
opment of cell reprogramming technology were
quantum leaps as they led to the achievement of reju-
venation by cell reprogramming which in turn
constitutes a paradigm shift in gerontology. A major
consequence of these discoveries is the emerging view
that aging is an epigenetic process and that somewhere
in the genome of somatic cells, there is a viable genetic
program that can be set in motion by a small number of
master genes. The purpose of this putative program
seems to be the reprogramming of somatic cells into
blastocyst-like, pluripotent embryonic stem cells. Al-
though at present we know virtually nothing about the
location of this hypothetic rejuvenation program, let
alone its structure and mechanism of action, we do
know how to turn on the program even in somatic cells
from very old individuals. We have discovered a power-
ful tool designed by nature and perfected during millions
of years of evolution and have learned how to use it to
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goal of understanding the molecular mechanisms in-
volved in pluripotency factor-mediated rejuvenation is
not nearly as imperative as the objective of learning how
to implement cell reprogramming technology in nontrans-
genic old animals and humans in order to erase epigenetic
marks of aging without removing epigenetic marks of cell
identity. The rate of progress in biotechnology is increas-
ingly fast, approaching an exponential curve. It is there-
fore reasonable to expect that clinical approaches to stop
aging and even rejuvenate aged humans will be developed
within the next two or three decades.
It has been stated that “any sufficiently advanced tech-
nology is indistinguishable from magic” [35]. Now, it
seems that the magic of human technology is making
rejuvenation possible.
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